

病院長からのご挨拶 石黒直樹

A Message from the Director of Nagoya University Hospital
ISHIGURO, Naoki



病院長 | 石黒直樹

名古屋大学医学部卒業。医学博士。
名古屋大学医学部附属病院長。名
古屋大学医学部附属病院副病
院長を経て、2013年より現職。専門分
野は整形外科学。

Hospital Director | ISHIGURO, Naoki

MD, PhD degrees from Nagoya
University School of Medicine and
Graduate School of Medicine.
Director of Nagoya University
Hospital, since 2013, previously
vice-director. Field of Specialization:
Orthopedic Surgery.

世界を視野に進化を続ける

臨床研究中核病院として国際水準の研究を展開する、名古屋大学医学部附属病院。
地域の医療をリードするとともに、新たな医療開発、国際化にも力を注ぎ、
世界を視野に着実に進化を続けています。

Continuing to evolve to meet international needs

Nagoya University Hospital is a Core Clinical Research Hospital advancing research that meets world-class standards.

In addition to leading community medical care efforts, our hospital focuses on developing new treatments and globalization, continuing to make steadfast progress aimed at the world as a whole.

期待に応える新棟誕生

名古屋大学医学部附属病院は、1871(明治4)年、名古屋藩評定所跡に設置された公立の仮病院を起源に、地域の皆様のご理解とご支援のもと発展を遂げてきました。現在は県内外から多くの患者さんが来院され、当院の医療は高い評価をいただいています。反面、手術までの待機時間が問題になっており、解決の一手として、2018年から中央診療棟B^{*1}が稼働する予定です。ICUや手術室のほか、がんの診断・治療に力を発揮する内視鏡室や化学療法室、放射線治療室も拡充し、患者さんのニーズに最先端の医療で応えていきます。新棟の誕生は既存施設の機能の再配分にもつながり、小児がん拠点病院として重視する小児医療の充実に弾みをつけるものになるでしょう。いずれは小児医療センターとして院内の総合周産期母子医療センターと連携し、出生前診断から出生直後、成人後の治療まで、生涯にわたる高度な医療のさらなる充実を図っていきます。

新しい医療を患者さんに

2016年12月には、当院の心不全治療の実績が評価され、中部圏初の心臓移植実施施設に認定されました。重症心不全治療の最後の砦として、心臓移植を待つ患者さんを当院が支えたいと願っています。移植医療については、今後も積極的に取り組んでいく予定です。また、当院は日本発の新たな医薬品や医療技術などの開発を主導する、臨床研究中核病院^{*2}でもあります。世界には未だ治療法のない病気が数多くあります。中央診療棟Bに、世界で初めてヒトに新しい薬や治療を提供する病床を設けるなど、患者さんの希望となる新しい医療開発に挑んでいきます。加えて、臨床研究中核病院は患者申出療養制度の実施施設の役割も担っています。患者さんから申し出があれば、日本では未承認の治療や薬の提供が可能となり、治療の選択肢を広げることができます。いずれにせよ、これまで治らなかった病気を治すために、日本初、世界初の取り組みを進めることが当院の役割です。

国際化とIoT化を推進

今後、さらに拡大していきたいのが医療の国際化です。既にアジアを中心に海外進出を行っていますが、海外からも患者さんに来院いただける世界の名大病院にならなければなりません。そのためには医療の質と患者安全が国際水準にあると証明する必要があります。国際医療機能評価機関JCI^{*3}の認定取得を目指して準備を進めているところです。取得すれば医薬品開発の認可も得やすくなり、医療の発展の足掛かりとなるでしょう。

一方、日本社会を覆う人手不足の問題は病院も例外ではありません。そこで夜間の配送業務を担う運搬ロボットの導入を手始めに、病院のIoT^{*4}化を進めたいと思っています。将来、病院の機器や患者さんのデータなどをネットワーク化できれば、医療面や安全面の質もさらに向上できるものと考えます。より高度で安心な医療を患者さんに提供するために、当院は前進を続けています。その一端を本誌から感じ取っていただければ幸いです。

※1/中央診療棟B

高度医療を行うための先端医療機器や手術室、ICU、抗がん剤治療、放射線治療などを行う専用の治療室を整備する施設。2018年稼働予定。

※2/臨床研究中核病院

国際水準の臨床研究や医師主導治験の中心的な役割を担う病院。医療法に定められた高水準の承認要件をすべて満たすことが求められ、現在11の医療機関が承認されている。

※3/国際医療機能評価機関JCI (Joint Commission International)

米国の国際的な医療施設評価認証機関。「患者安全」「感染管理」など、さまざまな項目から医療の質と安全を厳しく評価し、世界水準に達した施設に認証が与えられる。

※4/IoT

Internet of Things(モノのインターネット)の略。あらゆるモノがインターネットを通じて接続され、モニタリングやコントロールを可能にする仕組み。

A new hospital building to meet patient needs

Nagoya University Hospital's history began in 1871 when it was first established as a temporary public hospital at the former site of the Nagoya Domain conference chamber. In the ensuing 140 years, with the understanding and support of the local community, it has developed into the highly-respected institution that it is today.

Currently, many patients visit our hospital from both within Aichi prefecture and elsewhere, and our hospital has a distinguished reputation for providing outstanding healthcare. This has, however, led to excessive wait times for patients needing surgery. To resolve this issue, the Central Consultation Building B*¹ will open its doors in 2018. In addition to an ICU and operating rooms, these expanded facilities will include dedicated rooms for endoscopy, chemotherapy, and radiation therapy. These will have a huge impact on the diagnosis and treatment of cancers, and assist in better meeting patient needs by providing state-of-the-art medical care.

The new hospital building will also allow reassignment of existing facilities. This will permit us to galvanize our pediatric care program, an initiative we hold vital as a Childhood cancer hub hospital. Eventually, we hope to establish a pediatric medical center by collaboration with the Center for Maternal - Neonatal Care, allowing for complete healthcare coverage from prenatal diagnosis to the immediate postnatal period, and further extending into adult care, thus ensuring advanced medical treatment for the entirety of a patient's lifetime.

New treatments for our patients

In December 2016, we were designated the first medical institution in Central Japan to perform cardiac transplantations based on recognition of our success in treating patients with heart failure. As the last bastion of hope in severe heart failure, we will strive to support those patients awaiting cardiac transplantation. Our goal is to become even more actively involved in transplantation medicine.

Our facility is also one of the Core Clinical Research Hospitals*² that lead development of new drugs and new medical technologies from within Japan. There are still many diseases around that world where no treatment is available. In Central Consultation Building B, we will establish beds where

first-in-human studies will be conducted in Japan before anywhere else in the world, allowing us to develop new medical treatments to meet patient needs. Moreover, Core Clinical Research Hospitals also fulfill the role of facilities that offer patient-requested recuperation treatment. If the patient requests this type of treatment, then our facility is able to provide them with therapies and drugs that are yet to be approved in Japan, expanding potential treatment choices. To cure diseases that were previously incurable, we have a responsibility to move forward with first-in-Japan or first-in-the-world treatment initiatives.

Promoting Globalization of Education and IoT

In the future, we hope to work towards globalization of medical care. Although we are already expanding internationally, especially within Asia, we must become internationally ubiquitous as "Meidai Hospital" where patients will come from around the world. To achieve this goal, we must prove that our quality of medical care and assurance of patient safety meets the international standards of care. We are currently preparing for an evaluation from the Joint Commission International (JCI)*³, in order to gain accreditation. If we are accredited, then it will be easier to receive approval for drug development, and this will provide us with a foothold towards further advances in medical care. However, hospitals are no exception to the manpower shortage that plagues Japanese society today. Starting with the introduction of a transport robot to take on night-time delivery duties, we hope to move forward with an IoT*⁴ of the hospital. In the future, as our goal, we will network hospital medical devices and patient data to enhance improvement in healthcare and the quality of safety measures.

By providing patients with more advanced and safer medical treatment, our hospital aims to continue making progress in healthcare. If you have sensed our dedication towards these goals from this brochure, then it will have fulfilled its purpose.



*1/Central Consultation Building B

A facility that houses cutting-edge medical devices, operating rooms, an ICU, and treatment rooms that allow highly advanced anticancer chemotherapy, or radiation therapy. To be opened in 2018.

*2/Core Clinical Research Hospitals

Hospitals that fulfill core functions in world-class clinical research and investigator-initiated trials. Facilities are expected to meet highly selective approval conditions as specified under Medical Service Law. Currently, 11 medical facilities in Japan have been approved as core centers.

*3/ Joint Commission International (JCI) (of the United States)

An international accreditation council that evaluates the hospital functions of medical institutions. Various aspects such as "Patient safety" and "Infection control," are strictly evaluated and facilities that fulfill international standards of care receive accreditation.

*4/IoT

Abbreviation for an Internet of Things. All things are connected via the internet, allowing for a network that allows monitoring and control.